๐ฆ Malaria Vaccines
By Dr. Sk Sabir Rahaman, MBBS, MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD
๐น Introduction
-
Malaria is one of the most important parasitic diseases worldwide, mainly caused by Plasmodium falciparum and P. vivax.
-
Despite control measures (vector control, insecticide-treated nets, chemoprophylaxis), malaria remains a leading cause of morbidity and mortality, especially in sub-Saharan Africa and parts of Asia, including India.
-
Historic milestones:
-
RTS,S/AS01 (Mosquirix) → WHO recommendation in 2021 (first malaria vaccine).
-
R21/Matrix-M → WHO prequalification in 2023, with higher efficacy and large-scale Indian production.
-
๐น Objectives of Malaria Vaccination
-
Reduce malaria incidence, morbidity, and mortality in endemic regions.
-
Complement existing measures (bed nets, insecticides, ACTs, chemoprophylaxis).
-
Prevent severe malaria and deaths in children (the most vulnerable group).
-
Support long-term malaria elimination programs.
๐น Types of Malaria Vaccines
1. RTS,S/AS01 (Mosquirix)
-
WHO approval: 2021 (first malaria vaccine).
-
Type: Recombinant protein vaccine – circumsporozoite protein (CSP) of P. falciparum fused with hepatitis B surface antigen + AS01 adjuvant.
-
Efficacy: ~30–36% against severe malaria.
-
Schedule: 3 primary doses + 1 booster.
-
Limitations:
-
Protection wanes over time.
-
Only partial efficacy.
-
Requires multiple doses.
-
2. R21/Matrix-M
-
WHO prequalification: 2023.
-
Developed by Oxford University; manufactured by Serum Institute of India (Pune) → ensures large-scale, low-cost supply.
-
Efficacy: ~70–75% (superior to RTS,S).
-
Advantages:
-
Higher efficacy.
-
Lower cost → feasible for mass rollout.
-
Scalable → expected to become mainstay vaccine in endemic regions.
-
3. Next-Generation Vaccines (in development)
-
Whole sporozoite vaccines (PfSPZ) → irradiated or genetically attenuated sporozoites.
-
Transmission-blocking vaccines → target gametocytes, prevent spread via mosquitoes.
-
mRNA vaccines → experimental, strong immune responses.
-
Viral-vectored vaccines (AdFalciVax, etc.) → under clinical trials.
๐น Indications
-
RTS,S: Children aged 5–17 months in moderate-to-high P. falciparum endemic regions (e.g., sub-Saharan Africa).
-
R21: Same group; broader rollout expected from 2024 onwards.
-
Adults & Travelers: Not yet approved, but studies are ongoing.
๐น Contraindications
-
Severe allergic reaction (anaphylaxis) to vaccine components.
-
Severe acute illness with fever → vaccination deferred.
-
Not indicated for infants <5 months or adults (insufficient data).
๐น Clinical Importance in Public Health
-
First vaccines to reduce malaria-related hospitalizations and deaths.
-
Pilot data (RTS,S in Ghana, Kenya, Malawi):
-
↓ 22% severe malaria hospitalizations.
-
↓ 13% all-cause child mortality.
-
-
Reduce burden on health systems and improve child survival.
-
Function as a complementary tool alongside vector control and chemoprevention.
๐น Indian Perspective
-
Burden: 2–3 million malaria cases annually. India contributes ~66% of malaria cases in WHO South-East Asia Region.
-
Species trend:
-
P. falciparum → tribal, forested, northeastern states.
-
P. vivax → more common in urban areas.
-
-
National Framework for Malaria Elimination (NFME 2016–2030) → Goal: malaria-free India by 2030.
-
Role of Vaccines in India:
-
R21/Matrix-M manufactured in Pune → India as global supplier for Africa & Asia.
-
Selective introduction in high-burden states (Odisha, Chhattisgarh, Jharkhand, Northeast).
-
Must be integrated with existing programs (bed nets, IRS, ACTs).
-
๐น Future Perspectives
-
Combination strategies: Vaccination + chemoprophylaxis.
-
Next-generation platforms: PfSPZ, transmission-blocking, mRNA.
-
Global rollout: R21 likely to dominate due to efficacy and affordability.
-
Ultimate goal: Integrated vaccination + vector control → elimination of malaria.
๐น Conclusion
-
Malaria vaccines mark a landmark achievement in infectious disease control.
-
RTS,S (2021) → first approved vaccine, modest efficacy.
-
R21 (2023, Indian-manufactured) → higher efficacy, affordable, scalable.
-
Though not 100% protective, vaccines significantly reduce severe disease and child mortality.
-
With India’s NFME 2030 goal and role as a vaccine hub, malaria vaccination is poised to become central to elimination strategies both in India and endemic Africa.
✅ Key Take away:
“Malaria vaccines (RTS,S & R21) represent the first successful attempt to immunize against a parasitic disease. They are not curative, but by reducing severe malaria and child mortality, they act as vital adjuncts to existing control measures and are a cornerstone in the global goal of malaria elimination.”
๐ Visit My Website for Full Article & other Free PDFs and Resources
Comments
Post a Comment